Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of the fact that the blood supply of HCC comes predominantly from the hepatic artery compared with the surrounding normal liver which is predominantly supplied by portal venous blood. The intent is to deprive the HCC of its blood supply, leading to the death of the tumor. Traditionally, various methods have been used to block the HCC blood supply, but improvements are needed. This study will investigate a new agent desig

Trial Details

NCT ID
NCT04601428
Phase
EARLY_PHASE1
Sponsor
Koo Foundation Sun Yat-Sen Cancer Center
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • IA therapy of HCC with CSR02-Fab-TF
Locations (sample)
  • Tainan, North Dist., Taiwan|22.99083,120.21333
  • Taipei, Pei-Tou Dist., Taiwan|25.05306,121.52639
  • Taipei, Zhongzheng Dist., Taiwan|25.05306,121.52639
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Age ≥ 18 years
  • Diagnosis of HCC by at least one of the following criteria:
  • Histological confirmation;
  • Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion \> 1 cm with i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →